BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

638 related articles for article (PubMed ID: 15833831)

  • 1. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion.
    Zea AH; Rodriguez PC; Atkins MB; Hernandez C; Signoretti S; Zabaleta J; McDermott D; Quiceno D; Youmans A; O'Neill A; Mier J; Ochoa AC
    Cancer Res; 2005 Apr; 65(8):3044-8. PubMed ID: 15833831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma.
    Ochoa AC; Zea AH; Hernandez C; Rodriguez PC
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):721s-726s. PubMed ID: 17255300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis.
    Sinha P; Clements VK; Ostrand-Rosenberg S
    Cancer Res; 2005 Dec; 65(24):11743-51. PubMed ID: 16357187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes.
    Rodriguez PC; Ernstoff MS; Hernandez C; Atkins M; Zabaleta J; Sierra R; Ochoa AC
    Cancer Res; 2009 Feb; 69(4):1553-60. PubMed ID: 19201693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of arginase II on L-arginine depletion and cell growth in murine cell lines of renal cell carcinoma.
    Tate DJ; Vonderhaar DJ; Caldas YA; Metoyer T; Patterson JR; Aviles DH; Zea AH
    J Hematol Oncol; 2008 Sep; 1():14. PubMed ID: 18817562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloid-derived suppressor cells infiltrate the heart in acute Trypanosoma cruzi infection.
    Cuervo H; Guerrero NA; Carbajosa S; Beschin A; De Baetselier P; Gironès N; Fresno M
    J Immunol; 2011 Sep; 187(5):2656-65. PubMed ID: 21804013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells.
    Liu Y; Yu Y; Yang S; Zeng B; Zhang Z; Jiao G; Zhang Y; Cai L; Yang R
    Cancer Immunol Immunother; 2009 May; 58(5):687-97. PubMed ID: 18828017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-educated CD11bhighIalow regulatory dendritic cells suppress T cell response through arginase I.
    Liu Q; Zhang C; Sun A; Zheng Y; Wang L; Cao X
    J Immunol; 2009 May; 182(10):6207-16. PubMed ID: 19414774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes.
    Valenti R; Huber V; Filipazzi P; Pilla L; Sovena G; Villa A; Corbelli A; Fais S; Parmiani G; Rivoltini L
    Cancer Res; 2006 Sep; 66(18):9290-8. PubMed ID: 16982774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nature of myeloid cells expressing arginase 1 in peripheral blood after trauma.
    Bryk JA; Popovic PJ; Zenati MS; Munera V; Pribis JP; Ochoa JB
    J Trauma; 2010 Apr; 68(4):843-52. PubMed ID: 19996805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway.
    Haile LA; von Wasielewski R; Gamrekelashvili J; Krüger C; Bachmann O; Westendorf AM; Buer J; Liblau R; Manns MP; Korangy F; Greten TF
    Gastroenterology; 2008 Sep; 135(3):871-81, 881.e1-5. PubMed ID: 18674538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded Vgamma9Vdelta2 T cells from renal cell carcinoma patients.
    Viey E; Lucas C; Romagne F; Escudier B; Chouaib S; Caignard A
    J Immunother; 2008 Apr; 31(3):313-23. PubMed ID: 18317356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer.
    Liu CY; Wang YM; Wang CL; Feng PH; Ko HW; Liu YH; Wu YC; Chu Y; Chung FT; Kuo CH; Lee KY; Lin SM; Lin HC; Wang CH; Yu CT; Kuo HP
    J Cancer Res Clin Oncol; 2010 Jan; 136(1):35-45. PubMed ID: 19572148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses.
    Rodriguez PC; Quiceno DG; Zabaleta J; Ortiz B; Zea AH; Piazuelo MB; Delgado A; Correa P; Brayer J; Sotomayor EM; Antonia S; Ochoa JB; Ochoa AC
    Cancer Res; 2004 Aug; 64(16):5839-49. PubMed ID: 15313928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptidome from renal cell carcinoma contains antigens recognized by CD4+ T cells and shared among tumors of different histology.
    Tassi E; Facchinetti V; Seresini S; Borri A; Dell'antonio G; Garavaglia C; Casorati G; Protti MP
    Clin Cancer Res; 2006 Aug; 12(16):4949-57. PubMed ID: 16914584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells.
    Yang R; Cai Z; Zhang Y; Yutzy WH; Roby KF; Roden RB
    Cancer Res; 2006 Jul; 66(13):6807-15. PubMed ID: 16818658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients.
    Mandruzzato S; Solito S; Falisi E; Francescato S; Chiarion-Sileni V; Mocellin S; Zanon A; Rossi CR; Nitti D; Bronte V; Zanovello P
    J Immunol; 2009 May; 182(10):6562-8. PubMed ID: 19414811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells.
    Donkor MK; Lahue E; Hoke TA; Shafer LR; Coskun U; Solheim JC; Gulen D; Bishay J; Talmadge JE
    Int Immunopharmacol; 2009 Jul; 9(7-8):937-48. PubMed ID: 19362167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloid-derived suppressor cells in mammary tumor progression in FVB Neu transgenic mice.
    Abe F; Dafferner AJ; Donkor M; Westphal SN; Scholar EM; Solheim JC; Singh RK; Hoke TA; Talmadge JE
    Cancer Immunol Immunother; 2010 Jan; 59(1):47-62. PubMed ID: 19449184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development.
    Greifenberg V; Ribechini E; Rössner S; Lutz MB
    Eur J Immunol; 2009 Oct; 39(10):2865-76. PubMed ID: 19637228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.